All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Brenda Sandmaier, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?

How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?

Sandmaier outlines preliminary data from a phase I dose escalation trial that observed conditioning with the radiolabeled anti-CD45 antibody, 211-At-BC8-B10. The study involved patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant. She highlights promising early data for toleration and efficacy of this conditioning regimen.

 

Share: